Objectives: Despite the widespread use of the leuprorelin 3-month depot in central precocious puberty (CPP), its clinical efficacy and patient follow-up remain unexplored. This study aimed to compare the clinical indicators of the leuprorelin 3-month depot and triptorelin 1-month depot following treatment in a CPP cohort to understand the therapeutic effect of the former.Methods: A retrospective analysis was performed on 60 children diagnosed with progressive idiopathic CPP or precocious puberty who received at least 24 months of treatment at the hospital. The treatment involved leuprorelin 3-month depot for 18 participants, triptorelin 1-month depot for 16 participants, and a combination of both drugs for 26 participants. Anthropometric, biochemical, and bone age (BA) data were examined before treatment and every 12 months during treatment.Results: Before treatment, no statistical differences were noted in the baseline levels of sex hormones (oestradiol (E2), luteinising hormone (LH), and follicle-stimulating hormone (FSH)) among the triptorelin 1-month depot, leuprorelin 3-month depot, and combination therapy groups (P>0.05). However, the serum testosterone levels among participants were statistically significant (P < 0.05). After 1 and 2 years of treatment, no statistically significant differences were noted in the baseline levels of sex hormones (E2, LH, and FSH) among the three groups (P>0.05). At baseline, no statistical differences were found in BA, height, or weight among the groups (P>0.05). After 1 and 2 years of treatment, no statistically significant differences were observed in the growth rate, maturity, or BA growth rate of the participants in all three groups (P>0.05).Conclusions: The therapeutic effects of the triptorelin 1-month and leuprorelin 3-month depots were equivalent. Furthermore, treatment with leuprorelin 3-month depot is cost-effective compared with the other options . It reduces the number of injections administered to paediatric patients, the time spent on medical visits, and improves compliance, leading to greater acceptance among patients.